Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2017
At a glance
- Drugs GSK 239512 (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 12 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 May 2014 Planned End Date changed from 1 Oct 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
- 18 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.